Showing results (111-120 of 408) with videos related to

Sort By:
Pageof 41
The Oncologist|April 23, 2020
Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular LymphomaFrédérique St-Pierre, Stephen M Broski, Betsy R LaPlant, et al.
Blood Cancer Journal|November 14, 2018
Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphomaJing Jing Han, Megan O'byrne, Mary J Stenson, et al.
Transgender Health|October 9, 2023
Factors Associated with Time to Receiving Gender-Affirming Hormones and Puberty Blockers at a Pediatric Clinic Serving Transgender and Nonbinary YouthDiana M Tordoff, Gina M Sequeira, Alic G Shook, et al.
British Journal of Haematology|June 29, 2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological originMyron S Czuczman, Julie M Vose, Thomas E Witzig, et al.
Clinical Lymphoma & Myeloma|November 21, 2007
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphomaGregory A Wiseman, Peter S Conti, Katie Vo, et al.
Blood Cancer Journal|March 14, 2018
Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine eraRebecca L King, Grzegorz S Nowakowski, Thomas E Witzig, et al.
Leukemia Research|August 2, 2006
Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progressionMichael Kline, Kathleen Donovan, Linda Wellik, et al.
American Journal of Hematology|December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycinVijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
Blood Advances|February 26, 2021
Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphomaCatherine S Diefenbach, Brandilyn A Peters, Huilin Li, et al.
Leukemia & Lymphoma|March 15, 2017
Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issueAnthony Q Pham, Stephen M Broski, Thomas M Habermann, et al.
Pageof 41